Company Description
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke.
This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery.
It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics.
The company was founded in 1886 and is based in New Brunswick, New Jersey.
| Country | United States |
| Founded | 1886 |
| IPO Date | Sep 24, 1944 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 138,100 |
| CEO | Joaquin Duato |
Contact Details
Address: One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 United States | |
| Phone | 732 524 0400 |
| Website | jnj.com |
Stock Details
| Ticker Symbol | JNJ |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000200406 |
| CUSIP Number | 478160104 |
| ISIN Number | US4781601046 |
| Employer ID | 22-1024240 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joaquin Duato | Chief Executive Officer and Chairman |
| Jennifer L. Taubert | Executive Vice President and Worldwide Chairman of Innovative Medicine |
| Dr. John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine, Research & Development |
| Timothy Schmid | Executive Vice President and Worldwide Chairman of MedTech |
| Robert J. Decker Jr. | Controller and Chief Accounting Officer |
| James Swanson | Executive Vice President and Chief Information Officer |
| Jessica Moore | Vice President of Investor Relations |
| Dirk Brinckman | Chief Compliance Officer |
| Elizabeth Forminard J.D. | Executive Vice President and Chief Legal Officer |
| Kristen Blair Mulholland | Executive Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2025 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 12, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 12, 2025 | ARS | Filing |
| Mar 12, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 28, 2025 | CERT | Certification by an exchange approving securities for listing |
| Feb 26, 2025 | 8-A12B | Registration of securities |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 144 | Filing |
| Feb 21, 2025 | 424B2 | Prospectus |
| Feb 20, 2025 | 8-K | Current Report |